Previously we found that outbred male Sprague-Dawley rats can be classified as either low or high cocaine responders (LCRs or HCRs, respectively), based on their open-field locomotor response to acute cocaine (COC; 10 mg/kg, i.p.). Here, we extended this analysis to amphetamine (AMPH; 0.5, 1, and 5 mg/kg, i.p.) and found that the individual differences in behavioral activation were not as pronounced as with COC. This was confirmed with observational analysis of behaviors. Differences in drug-induced activation could involve differential dopamine transporter (DAT) function/trafficking. To address this possibility, we measured [ 3 H]DA uptake into dorsal striatal synaptosomes prepared from rats injected 30 min earlier with saline, COC, or AMPH to determine DAT activity, and radioligand binding to determine the total number of DATs. Striatal [ 3 H]DA uptake in COC-treated HCRs was significantly higher than in LCRs. Furthermore, regardless of LCR/HCR classification, uptake in individual COC-treated rats was significantly correlated with their locomotor behavior in the 30 min after drug administration. In contrast, AMPH-treated rats did not differ in uptake, nor were uptake and locomotor activity correlated. DAT number did not differ between LCRs or HCRs, or between AMPH-treated rats. In addition, when individual differences in COC-induced behavior were no longer detected in LCRs and HCRs 1 week after initial classification, uptake was also similar. Together, these results suggest that a difference in expression of functional DATs on the cell surface contributes to the individual differences observed in COC-induced, but not AMPH-induced, behavioral activation of rats.
INTRODUCTION
The abuse potential of the psychomotor stimulant cocaine (COC) is related to its ability to bind to the dopamine transporter (DAT) and prevent reuptake of released dopamine (DA) (see Ritz et al, 1987; Kuhar et al, 1991) . Low doses of COC generally produce locomotor activation. However, considerable variability (eg different magnitudes) in the behavioral responsiveness of individual animals is often observed. These individual differences have been observed both in outbred and inbred strains of mice (Ruth et al, 1988; George and Ritz, 1990; Henricks et al, 1997; Marley et al, 1998; Rocha et al, 1998) . Likewise, variability in COC-induced behaviors has been observed in rats, predominantly in the propensity of rats, often initially classified as either low or high responders to novelty, to self-administer drug (Glick et al, 1994; Piazza et al, 2000) , or to become behaviorally sensitized (Hooks et al, 1991a; Hooks et al, 1992; Djano and Martin-Iverson, 2000; Chefer et al, 2003) . Differences in initial responsiveness of humans to cocaine also reflect both genetic and environmental influences and are one factor that determines whether or not an individual will become addicted to cocaine (Haertzen et al, 1983; Davidson et al, 1993) .
d-Amphetamine (AMPH) is another psychomotor stimulant that interacts with the DAT. However, unlike COC, AMPH is a substrate for the DAT, thereby entering the nerve terminal, disrupting DA storage in synaptic vesicles, and releasing DA by reversing the DAT (Sulzer and Rayport, 1990; Seiden et al, 1993; Sulzer et al, 1995; Floor and Meng, 1996) . Individual differences in AMPH-induced behaviors have also been reported and, like COC, particularly in rats previously classified by their response to novelty (Segal and Schuckit, 1983; Segal and Kuczenski, 1987; Piazza et al, 1989; Hooks et al, 1991b; Exner and Clark, 1993; Bevins et al, 1997; Cools et al, 1997; DeSousa et al, 2000; Klebaur et al, 2001) .
Recently, our laboratory reported that outbred, male Sprague-Dawley rats exhibit a wide range of behavioral responses when they are given an acute injection of COC (10 mg/kg, i.p) in an open-field environment. We found that the median distance traveled in the 30 min following injection can be used to classify rats as either low or high COC responders (LCRs or HCRs, respectively) (Sabeti et al, 2002; . This behavioral variability, which is not due to differences in COC pharmacokinetics , appears to be related to individual differences in the function of the DAT in the dorsal striatum (dSTR) and nucleus accumbens (NAc; Sabeti et al, 2002) . Specifically, by measuring clearance of exogenous DA in the dSTR and NAc, which has been shown to reflect the number of functional DA uptake sites (Cass et al, 1992; Hebert and Gerhardt, 1999) , we demonstrated that the magnitude of COC-induced changes in clearance and locomotor activation of individual rats are strongly correlated (Sabeti et al, 2002) . The functional differences in DAT are not due to differences between LCRs and HCRs in NAc total DAT number or affinity, or DAT affinity for COC . The source of this functional difference may instead be due to differences in either basal or COC-induced changes in cell surface expression of DAT.
It is well documented that psychomotor stimulants that are DAT substratesFsuch as AMPH, methamphetamine, and methylenedioxymethamphetamineFinduce rapid downregulation of DAT cell surface expression in vitro or ex vivo (Kokoshka et al, 1998; Fleckenstein et al, 2000; Saunders et al, 2000; Hansen et al, 2001; Gulley et al, 2002; . Typically, COC has been shown to have the opposite effect on DAT, increasing its cell surface expression (Daws et al, 2002; Little et al, 2002 ; but see Chi and Reith, 2003) . Therefore, the first aim of the present study was to examine [ 3 H]DA uptake into synaptosomes prepared from dSTR of animals pretreated with an acute injection of 10 mg/kg COC 30 min prior to killing. This measure of DAT function, when combined with radioligand binding assays to determine the total number of DATs, has been used previously as an indirect measure of DAT cell surface expression (Pristupa et al, 1998; Kokoshka et al, 1998) . We hypothesized that differences in the locomotor response to COC could be due, at least in part, to differences in basal or COC-induced changes in DAT cell surface expression in the dSTR.
A second aim was to examine whether, similar to COC, AMPH produces considerable individual variability in locomotor activation of outbred, male Sprague-Dawley rats. This was particularly interesting to assess given the opposite regulation of DAT surface expression induced by AMPH and COC (see above). Thus, we also tested the extent to which differences in DAT function and/or expression in the dSTR might mediate AMPH-induced behavioral variability.
MATERIALS AND METHODS

Animals
Outbred, male Sprague-Dawley rats (200-300 g) were obtained from Charles River Laboratory (Sasco, Omaha, NE) and housed on a 12-h light/dark cycle with ad libitum food and water. All animal use procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Colorado Health Sciences Center.
Behavioral Characterization
On the day of behavioral characterization, rats were removed from the animal colony, housed individually, and allowed 1-2 h to habituate to the testing room. They were then placed in an open-field apparatus consisting of white laminate flooring and a clear acrylic box (16 00 Â 16 00 Â 15 00 ), which was surrounded by a photobeam frame (San Diego Instruments, San Diego, CA). The apparatus was enclosed in a sound-attenuating box (24 00 Â 24 00 Â 24 00 ) and illuminated by a white light bulb (4 W). Rats were given 90 min to habituate to the apparatus, at which time they were removed and injected (i.p.) with either saline (n ¼ 30), 10 mg/kg (À)COC HCl (n ¼ 82), or AMPH sulfate (0.5, 1, or 5 mg/kg; n ¼ 24, 56 or 12, respectively). They were returned to the apparatus for either 30 min (behavioral analysis followed by either [ 3 H]DA uptake or radioligand binding measurements) or 60 min (behavioral analysis only). A video camera connected to a VCR was used to record the rats' behavior for the 30 min before and the 30-60 min following injection. During testing, locomotor behavior was recorded as consecutive, horizontal photo beam breaks and subsequently converted to distance traveled (cm) per 5-min interval. The distance traveled in the 30 min postinjection was used to classify COC-treated rats as LCRs (whose locomotion fell below the median distance traveled) or HCRs (above the median). AMPH-treated rats were also classified based on the median, and are described as ABs (AMPH response below median) or AAs (above median).
For a subset of AMPH-treated animals (0.5 mg/kg, n ¼ 14; 1 mg/kg, n ¼ 18; 5 mg/kg, n ¼ 12), videotapes were observed by an individual unaware of the behavioral classification of the rats. Behaviors, scored in 1-min intervals for the 30 min before and 60 min following injection, included the following: (1) nonmovement, defined as inactivity or sleeping; (2) grooming, defined as movements directed against self that typically included forepaw movements over the body, scratching, licking, and face washing; (3) head movement/ sniffing, defined as movements of the head and/or sniffing that occurred in the absence of locomotion; (4) exploring, defined as locomotion around the apparatus that was continuous or occurred in repeated bouts and typically included head movements and sniffing; (5) stereotypy, defined as highly focused, repetitive head movements and sniffing, head bobs, and/or side-to-side head sways; and (6) rearing, defined as lifting both forepaws off the floor and ending when at least one forepaw returned to the floor. If a behavior was present for at least 10 s during the 1-min interval, it was scored as present (1 ¼ present, 0 ¼ absent). If no single behavior persisted for 10 s, the behavior expressed during the majority of the 1-min interval was scored as present. For rearing, each individual occurrence was tabulated.
Based upon [ 3 H]DA uptake results in the rats treated acutely with COC and previous behavioral results 1 week after COC treatment , a follow-up [ 3 H]DA uptake experiment was conducted in a separate group of saline-and COC-treated rats 1 week after their initial classification (see below). These rats were treated either twice with salineFon days 1 and 8 (n ¼ 8)For twice with 10 mg/kg COCFonce on day 1 when they were classified as either LCRs or HCRs and once 1 week later (day 8; n ¼ 16). After the initial treatment and classification, these rats were housed in the room in which the behavioral experiments took place on a 12-h light/dark cycle with ad libitum food and water. On day 8 following the 90-min habituation period in the same open-field apparatus in which day 1 behavior was tested, the behavior of the rats given COC on day 1 was assessed for 30 min following COC injection. All of the rats were then killed for [ 3 H]DA uptake measurements.
Synaptosome Preparation
At 30 min after injection with saline (n ¼ 18), 10 mg/kg COC (n ¼ 19 for day 1 uptake; n ¼ 16 for day 8), or AMPH (1 mg/ kg, n ¼ 16; 0.5 mg/kg, n ¼ 8), rats were decapitated and their dSTR were dissected on an ice-cold glass dish. The tissue was weighed, homogenized in a 0.32 M sucrose buffer (pH 7.4) using a Teflon pestle/glass homogenizer (Wheaton #358003; Millville, NJ) and centrifuged at 1000g for 12 min at 4 o C. The resulting pellet was discarded, and the supernatant was centrifuged at 16 000g for 12 min at 4 o C to isolate the synaptosomes in a P2 pellet. The pellet was then used immediately for [ Uptake was determined using a modified version of the method described by Fleckenstein et al (1997) . The P2 pellet was resuspended by gentle aspiration at a dilution of 15 mg/ ml of original tissue weight in a modified Kreb's assay buffer (in mM: 126 NaCl, 4.8 KCl, 1.3 CaCl 2 , 16 NaPO 4 , 1.4 MgSO 4 , 11 dextrose, 1 ascorbic acid; pH 7.4) that contained 1 mM pargyline. The re-suspended synaptosomes were then incubated with 0.5 nM [
3 H]DA for 3 min at 371C. Nonspecific uptake was defined with 1 mM COC. Except for this 3-min incubation, the synaptosomes were kept at 41C in order to minimize trafficking of DAT. Incubation with [ 3 H]DA was terminated by rapid vacuum filtration through 0.05% polyethylenimine-soaked filter paper (GF/B; Brandel, Gaithersburg, MD) and washed three times with 5 ml of icecold sucrose buffer (0.32 M). Radioactivity was quantified 24 h later by liquid scintillation spectroscopy. Protein levels in the resuspended pellet were quantified using the Bradford protein assay (Bradford, 1976) with bovine serum albumin as the standard.
DAT Binding
Prior to radioligand binding, P2 pellets were resuspended at a dilution of 10 mg/ml of wet tissue weight in buffer (in mM: 0.32 sucrose, 30 NaH 2 PO 4 , 15 Na 2 HPO 4 ; pH 7.4) by homogenization with a Polytron for 3 s. The synaptosomal membranes were incubated for 1 h in an ice bath with 5 nM [ 3 H]WIN 35 428 and increasing concentrations of unlabeled WIN 35 428 (0.3-3 mM). Nonspecific binding was defined with 30 mM benztropine. Incubation was terminated as described above, except that the wash buffer was an ice-cold sodium phosphate solution (in mM: 30 NaH 2 PO 4 , 15 Na 2 HPO 4 ; pH 7.4). Radioactivity was quantified and protein levels were determined as described above for the uptake assays.
Statistical Analyses
Data in the text are presented as mean7SD, except where noted. Data in the table and figures are presented as mean7SEM. The median of all treated animals for each drug and dose was used to separate animals into their respective categories (LCR or HCR for COC; AB or AA for AMPH).
For analysis of drug effects on locomotion, the distance traveled in centimeter was averaged into 15-min bins and compared using a one-way ANOVA and Tukey post hoc test (SigmaStat 3.0; SPSS, Inc., Chicago, IL). Frequency distributions of locomotor activity were analyzed using the Kolmogorov-Smirnov test and a kurtosis analysis. Differences between groups were analyzed using a mixed, twofactor ANOVA (group Â time, with time as the repeated measure) followed by pairwise comparisons of specific time points using the Tukey post hoc test. For behavioral observation categories, 1-min incidence scores were summed into 15-min bins and transformed into a frequency score by dividing the cumulative score by 15. This allowed the fraction of the 15-min interval to be calculated (eg 0.4 means the behavior was present in 40% of the 1-min intervals in a 15-min bin). The exception was rearing, which was tabulated as the total number of occurrences during a 1-min interval summed into 15-min bins. Drug effects were analyzed using a mixed two-factor ANOVA (group Â time, with time as the repeated measure) followed by pairwise comparisons of specific time points using the Tukey post hoc test.
Specific [ 3 H]DA uptake levels in the dSTR of LCRs/HCRs or ABs/AAs were expressed as a percent of uptake in salinetreated rats tested on the same day. Group differences (eg LCRs vs HCRs or ABs vs AAs) were analyzed using one-way ANOVA. In addition, linear regression was used to evaluate the relationship between specific [ 3 H]DA uptake and locomotor activation during the 30-min period following COC or AMPH injection. Note that due to technical problems with the assay, data from a [ 3 H]DA uptake experiment performed on rats treated on days 1 and 8 with saline (n ¼ 1) and COC (n ¼ 2) were excluded from the analysis.
Radioligand binding data were analyzed with nonlinear curve fitting for one-and two-site binding models to obtain affinity values (IC 50 and K i ; GraphPad Prism, GraphPad Software, Inc., San Diego, CA). The total number of binding sites (B max ) was determined using the formula described by DeBlasi et al (1989 
RESULTS
Behavior of Rats Treated with COC
The open-field locomotor activity of COC-treated, outbred male Sprague-Dawley rats is shown in Figure 1 . Before drug administration, all animals responded to the novel openfield apparatus with increased locomotion that diminished by 45 min, at which time most animals moved very little until after injection. At 90 min, rats were injected with 10 mg/kg COC (n ¼ 82). This resulted in increased locomotor activity over baseline, with rats traveling 920073940 cm (mean7SD) in the 30 min following drug injection. Animals whose behavior was below or above the median, 9430 cm/ 30 min, were designated as either LCRs or HCRs, respectively. Both LCRs and HCRs had a similar response to novelty ( Figure 1b ; the first 60 min of the time course). Following COC administration, the average distance traveled by LCRs was 594071880 cm/30 min and by HCRs was 12 50072450 cm/30 min.
Even though the distribution of COC-induced locomotor activity in the individual rats was within the range of normality (Figure 1a ; D ¼ 0.068, p40.05; KolmogorovSmirnov test), the scatter about the mean appeared somewhat greater than that of an ideal unimodal curve. In confirmation of this observation, kurtosis analysis revealed that the COC distribution was somewhat flat (kurtosis ¼ À0.72; zero represents an ideal bell-shaped distribution). In addition to being broader, the frequency distribution of the COC-treated rats also had bimodal characteristics (Figure 1a) . At the time of maximal behavioral activation (30 min after injection of 10 mg/kg COC), a subgroup of rats was killed, and dSTR synaptosomes were prepared in order to assess whether specific [ 3 H]DA uptake differed between LCRs (mean distance traveled: 617072220 cm/30 min, n ¼ 10) and HCRs (12 20072780, n ¼ 9). Owing to day-to-day variability in the absolute values of uptake (range ¼ 1.56-3.94 pmol/mg protein/3 min, across 10 experiments in saline-treated rats), data for each of the drug-treated rats were normalized as a percent of the uptake for a control animal treated with saline and assayed on the same day (see Materials and Methods). Specific the mean (7SEM) values (non-normalized) of uptake in LCRs (2.1070.15 pmol/mg protein/3 min) and HCRs (2.9170.41 pmol/mg protein/3 min) were also below and above, respectively, the mean uptake measured in saline-treated rats (2.4570.24 pmol/mg protein/3 min), but that these differences were not statistically significant (F 2,26 ¼ 1.80, p40.05). Additionally, regardless of the LCR/ HCR designation, specific [ 3 H]DA uptake was significantly correlated with distance traveled in the 30 min following COC injection, with rats that were more highly activated demonstrating greater uptake (Figure 2b Previous results demonstrated that when COC was administered to the rats 1 week after their initial injection and classification as LCRs or HCRs, the differences in COCinduced locomotor activity were no longer apparent . This observation provided a means to further test the relationship between the behavioral and DAT functional differences found after the initial COC administration in LCRs and HCRs. Therefore, rats were injected with 10 mg/kg COC on day 1 and classified as either LCRs (mean distance traveled: 584071780 cm/30 min, n ¼ 8) or HCRs (1280072630, n ¼ 6). After 1 week, on day 8, 10 mg/ kg COC was again administered to these rats, and locomotor activity was measured (Figure 3a) . Baseline locomotor activity on day 8 prior to COC injection was significantly elevated between 30 and 90 min in all rats compared to day 1. However, after the COC injection, the activity of LCRs and HCRs did not differ. Specific [ 3 H]DA uptake was assessed in dSTR synaptosomes prepared 30 min after COC-pretreatment on day 8 and, similar to locomotor activity, did not differ significantly between LCRs and HCRs ( Figure 3b ). As with our uptake experiments performed on day 1 (see above), data from COCtreated rats were normalized as a percent of the uptake for saline-treated control rat tested on the same day. However, the non-normalized mean (7SEM) values also revealed that uptake was similar across all groups (saline: 2.2570.21 pmol/mg protein/3 min; LCR: 2.3470.20 pmol/mg protein/ 3 min; HCR ¼ 2.4870.29 pmol/mg protein/3 min). Thus, on the first day, when LCRs and HCRs displayed considerable differences in COC-induced locomotor activity, HCRs displayed B32% greater uptake than LCRs; 1 week later, when LCRs and HCRs behaved similarly, HCRs only had B7% greater uptake.
Behavior of Rats Treated with AMPH
The open-field locomotor activity of saline-and 1 mg/kg AMPH-treated rats is shown in Figure 4 . All of the rats exhibited similar behavior during the first 90 min in the open field (Figure 4b ). After this period, rats were injected with either saline (n ¼ 13) or 1 mg/kg AMPH (n ¼ 56; Figure 4b ). Saline increased locomotor activity only during the first 15 min following injection; by 30 min, saline-treated rats moved very little. In contrast, AMPH increased locomotor activity over baseline, with rats traveling 13 40073190 cm (mean7SD) in the 30 min following injection. The frequency distribution of the locomotor activity during this time, although normal (D ¼ 0.093, 
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SK Briegleb et al p40.05), was more peaked than expected for an ideal bellshaped distribution (kurtosis ¼ 0.49; Figure 4a ). While individual differences in AMPH-induced locomotor behavior were apparent, they were not as pronounced as with COC and were less suggestive of two behavioral subgroups. However, in order to examine individual differences in the same way as with COC, we divided the AMPH-treated rats into two groups based on the median AMPH-induced activity (12 700 cm/30 min) for further behavioral assessment, as well as for uptake and radioligand binding experiments. Rats whose distance traveled in the 30 min after AMPH administration was below the median were classified as ABs, while those with AMPH-induced activity above the median were classified as AAs. The mean distance traveled in the 30 min after AMPH injection was 10 80071300 cm/30 min for ABs and 15 30071810 for AAs (Figure 4b ). Observational analysis of the behavior of a subset of rats (n ¼ 18) in the 60 min following injection with 1 mg/kg AMPH revealed, compared to baseline, decreases in nonmovement and increases in head movement/sniffing, exploring, and rearing ( Figure 5 ). Grooming and stereotypy were not differ from baseline (data not shown). No statistically significant differences were observed between ABs and AAs in any of the behavioral categories, with the exception of exploring ( Figure 5 ). Specifically, AMPH induced greater exploratory behavior in AAs than ABs only in the first 15 min following AMPH treatment. While head movement and sniffing behaviors were slightly elevated in ABs over AAs, these were not significantly different.
Since locomotor activation induced by 1 mg/kg AMPH was less suggestive of two subpopulations of rats, we tested two additional doses of AMPH (0.5 and 5 mg/kg) in separate groups of rats. As shown in Figure 4c and d, the frequency distributions for both doses were approximately normal (0.5 mg/kg: D ¼ 0.079, p40.05; 5 mg/kg: D ¼ 0.160, p40.05). Furthermore, both distributions were peaked and lacked prominent bimodal characteristics (kurtosis ¼ 0.51 and 1.23 for 0.5 and 5 mg/kg, respectively). Regardless of this relative homogeneity of responses, we split the animals into ABs and AAs based on the median (0.5 mg/kg: 9660 cm/30 min; 5 mg/kg: 14 600 cm/30 min) in order to test for potential individual differences (Figure 4e ). The mean distance traveled after injection of 0.5 mg/kg AMPH was 679472032 cm/30 min for ABs and 12 30072700 cm/ 30 min for AAs; following 5 mg/kg AMPH, the mean distance traveled was 12 70071310 and 17 90072950 for ABs and AAs, respectively.
Observational analysis revealed that after injection of 0.5 mg/kg AMPH, compared to baseline, nonmovement was reduced whereas head movement/sniffing and exploring were increased in both ABs and AAs (Figures 6a-c) . Rearing was increased relative to baseline only in AAs (Figure 6d ). Neither group displayed increases in grooming or stereotypy relative to baseline (data not shown). ABs and AAs differed in two of the scored behaviors. Specifically, AAs exhibited significantly more exploring during the first 30 min after injection (Figure 6c ). Rearing was also greater in AAs compared to ABs, although this difference was significant only during the 15-min interval concluding 30 min after injection (Figure 6d) .
Compared to the effects of the lower doses, 5 mg/kg AMPH produced a unique behavioral profile that was characterized by the emergence of repetitive, stereotyped behaviors. For example, normal head movement/sniffing was increased relative to baseline in ABs and AAs only during the first 15-min period following injection (Figure 7a ). Exploring and rearing were also significantly Differences in COC-and AMPH-induced activation of rats SK Briegleb et al elevated in both groups relative to baseline (Figure 7b and c). However, in rats classified as AAs, these increases were no longer significantly different from baseline beyond the 30-min period following AMPH injection. Instead, behavior in AA rats was characterized primarily by repetitive, stereotyped movements. These typically included focused 
SK Briegleb et al sniffing and head movements that occurred in the absence of locomotion (Figure 7d ). AB rats, in contrast, displayed high levels of exploring and rearing for the entire postdrug session. Although significant increases in focused stereotypy did not occur until 45 min after AMPH injection, the exploratory and rearing behavior exhibited by AB rats was clearly repetitive in nature. These rats typically traversed the perimeter of the open-field arena in either a clockwise or counterclockwise direction, stopping frequently to rear multiple times before continuing their locomotor pattern.
[
H]DA Uptake and DAT Binding in Rats Treated with AMPH
In order to compare results with those we found in rats given COC, we measured DAT function in a subset of animals given AMPH 30 min before killing. Since the behavioral effects of 5 mg/kg AMPH were characterized primarily by stereotyped responses that were not seen with 10 mg/kg COC, we measured specific [ 3 H]DA uptake only in rats given 1 or 0.5 mg/kg AMPH. At the time of near maximal behavioral activation (30 min after injection of 1 mg/kg AMPH), rats were killed and dSTR synaptosomes were prepared to assess whether specific [ 3 H]DA uptake differed between ABs (mean distance traveled: 10 8007 1260 cm/30 min, n ¼ 7) or AAs (14 80071770, n ¼ 9). In contrast with COC pretreatment, no difference in uptake was found between ABs (mean7SEM: 98.172.33% of saline-treated controls) and AAs (10476.07%) following the 30-min AMPH pretreatment. This was also evident by inspection of the non-normalized mean (7SEM) uptake values for each group (saline: 2.2470.11 pmol/mg protein/ 3 min; ABs: 2.2670.09 pmol/mg protein/3 min; AAs: 2.1970.13 pmol/mg protein/3 min). Furthermore, there was no correlation between uptake and locomotor activity in the AMPH-pretreated rats (r 2 ¼ 0.10, p40.05). Similar to LCRs and HCRs, no differences existed in the affinity or number of dSTR DAT binding sites among saline-pretreated controls, ABs, or AAs (Table 1) .
Specific [ 3 H]DA uptake was also assessed in a subset of rats treated with 0.5 mg/kg AMPH 30 min before killing to determine whether it differed between ABs (mean distance traveled: 62807965 cm/30 min, n ¼ 3) or AAs (12 0007755, n ¼ 5). As seen with 1 mg/kg AMPH, no difference in uptake was found between ABs (mean7SEM: 97.675.44% of saline-treated controls) and AAs (98.5711.0%). The nonnormalized mean uptake values were also similar (saline: 2.1370.37 pmol/mg protein/3 min; ABs: 2.0370.06 pmol/ mg protein/3 min; AAs: 1.9470.20 pmol/mg protein/3 min), and uptake and locomotor activity were not correlated (r 2 ¼ 0.04, p40.05).
DISCUSSION
Previously, we found that an acute injection of 10 mg/kg COC in outbred male Sprague-Dawley rats results in variable locomotor responsiveness suggestive of two subpopulations, LCRs and HCRs (Sabeti et al, 2002; . LCRs and HCRs also displayed differences in other behaviors such as nonmovement, head movement/sniffing, Figure 7 Compared to the lower doses of AMPH, the 5 mg/kg dose produced a unique behavioral profile characterized by repetitive, stereotyped movements. Behaviors exhibited by the rats (n ¼ 12) are presented as in Figure 5 . Following injection, neither group spent time in periods of nonmovement and grooming was not increased significantly above baseline in either group (data not shown). *po0.05, within-group comparison to the 15 min period before injection (ie time ¼ 90 min); # po0.05, AAs and ABs compared in the same time interval.
Differences in COC-and AMPH-induced activation of rats SK Briegleb et al and rearing. This behavioral variability is correlated with individual differences in DAT function (Sabeti et al, 2002) . Here, we again observed differential behavioral responsiveness consistent with two subpopulations in COC-pretreated rats. We then examined levels of DAT functional expression as a possible mechanism responsible for the behavioral variability, as well as extended this analysis to AMPHpretreated rats. Numerous mechanisms could explain individual differences in COC-induced behaviors. Several studies using inbred strains of mice have reported pharmacokinetic differences that could account for differential COC-induced locomotor activation Reith et al, 1987; Wiener and Reith, 1990; Jones et al, 1993) . Others have found increased number and affinity of DATs in the NAc of high, compared to low, novelty responders (Chefer et al, 2003) . However, we have demonstrated that these mechanisms are unlikely to explain the differential responsiveness of LCRs and HCRs to COC ; Table 1 ).
The fact that we found no differences in DAT B max values, however, does not obviate the possibility that the functional pool of DATs at the cell surface may differ. [ 3 H]WIN 35 428 binding to DAT in crudely purified membranes, as used here and by , measures total cellular transporters and would not detect differences in cell surface DATs between LCRs and HCRs. Thus, it is possible that differences in COC-induced cell surface expression of DAT could explain the differential COC-induced locomotor activation in LCRs and HCRs. In fact, it has been reported that COC rapidly alters trafficking and upregulates surfaceexpressed DAT in cell expression systems (Daws et al, 2002; Little et al, 2002 ) and brain (Daws et al, 2002 ; but see Chi and Reith, 2003) . HCRs, for example, might have sufficient DATs to take up DA released under basal conditions, but not when even a relatively low percentage of their DATs were inhibited by a low dose of COC. The increased extracellular DA would, in turn, stimulate locomotor activity. If this were the case, then the COC-induced increase in DATs in HCRs might reflect a secondary compensatory change to reduce the high levels of extracellular DA. In contrast, LCRs could have 'spare DATs' in their dSTR, relative to DA release; then COC blockade of a relatively low percentage of DATs might induce only a slight increase in their extracellular DA concentrations and locomotor activity. Alternatively, COC could induce greater increases in dendritic DATs in HCRs than LCRs. This would locally reduce DA concentrations and thereby decrease autoinhibition of DA neuronal firing, which might result in sufficiently increased DA release at the terminals to elevate locomotor activity to a greater extent in HCRs.
We tested the potential for differences in COC-induced trafficking of the DAT in LCRs and HCRs by measuring DAT function using [ Also, residual COC would have reduced, rather than increased [ 3 H]DA uptake, compared to controls. Indeed, Fleckenstein et al (1997) reported that the amount of drug in 'unwashed' synaptosomes (P2 pellets) was minimal and that uptake in P2 pellets and washed P2 pellets was similar.
Thus, our uptake experiments in COC-treated rats suggest that HCRs have greater cell surface expression of DAT. Importantly, specific [ 3 H]DA uptake showed a significant correlation with COC-induced locomotor activity in all of the rats, regardless of the LCR/HCR classification. Specifically, the rats that locomoted more after COC injection had greater Although we do not know the mechanism(s) underlying the loss of the LCR/HCR phenotypes 1 week after the initial COC administration, potential candidates include expression of behavioral sensitization in the LCRs and/or altered DA release and DAT regulation in the HCRs. Previously, we observed a loss of LCR/HCR behavioral differences after retest with COC because both LCRs and HCRs showed little COC-induced activation. In the present study, relative to day 1, COC-induced activation of HCRs was still reduced but COC-induced activation of LCRs appeared to be enhanced. However, this latter observation was due in large part to the elevated baseline activity prior to injection on day 8. We noted similar anticipatory behavior in our previous study, but it occurred only in HCRs and was of a relatively lesser magnitude, compared to their behavior on day 1. It is unclear why preinjection behavior was more robust in the present study, but it may indicate that the LCRs and HCRs tested here were more responsive to environmental cues and thereby developed stronger conditioned drugrelated responses.
Differences in basal levels of DAT expression could also explain the LCR/HCR phenotypes since chronically higher basal DA release might result in upregulated DAT expression and greater COC-induced increases in DA. However, to confirm this, LCRs would have to be distinguished from HCRs in the absence of drug. Unfortunately, since their responses to novelty are identical ; Figure 1 ), we have found no way so far to classify the rats, other than to administer COC. This fact also made it impossible for us to use data collected from saline-treated rats as a test for consistent, basal difference in DA uptake among Sprague-Dawley rats, which ultimately would have been classified as LCRs or HCRs if given COC. The alternative of administering COC to classify the rats and then waiting a relatively long period so that their DA systems returned to baseline is also problematic because even a single COC treatment induces changes in DA systems lasting longer than a month (Robinson et al, 1982; Zahniser, 1987, 1989) .
Unlike the initial pretreatment with 10 mg/kg COC, pretreatment with 1 mg/kg AMPH did not produce the same degree of individual behavioral variability. This is particularly apparent when the frequency distributions for locomotor activity induced by COC and AMPH are compared. The distribution of COC-treated rats had a broader spread and bimodal characteristics, compared with that of AMPH-treated rats, which had a more peaked distribution that lacked bimodal characteristics. Furthermore, observational analysis of rats treated with 1 mg/kg AMPH revealed no differences between ABs and AAs in behaviors other than exploring. Individual differences in AMPH-induced behaviors observed here could be less pronounced than those reported by others (eg Segal and Kuczenski, 1987) because of differences in the selection and classification of animals. We included all of the animals tested by separating them based on the median split, whereas some reports of individual differences have examined only the extremes of the distribution.
Since 1 mg/kg AMPH produced less prominent individual differences but slightly greater locomotor activation compared to 10 mg/kg COC, we also tested lower and higher doses of AMPH. Like 1 mg/kg, both 0.5 and 5 mg/kg AMPH resulted in peaked, unimodal-like distributions that did not strongly support the existence of two subgroups. After 0.5 mg/kg AMPH, however, ABs and AAs showed somewhat greater differences in AMPH-induced locomotor activity, compared to rats classified with 1 mg/kg AMPH. Observational analysis also revealed some differences between ABs and AAs in AMPH-induced exploring and rearing. However, individual differences were still not as great with AMPH as with COC (cf. Figures 1, 4-6 ; Sabeti et al 2002; . Whereas injections of 0.5 and 1 mg/kg AMPH produced behavioral effects that were similar, but of a different magnitude, to those produced by 10 mg/kg COC, rats injected with 5 mg/kg AMPH exhibited unique patterns of drug-induced behavior. Specifically, they displayed high levels of behavioral activation that were characterized by prolonged periods of repetitive, stereotyped movements. In some cases, stereotyped behavior was manifested as focused head movement and sniffing, whereas in other cases rats circled the chamber in one direction stopping for frequent bouts of rearing behavior. Similar effects induced by this dose of AMPH have been reported previously (eg Rebec et al, 1997) and are mediated by a number of factors including DA receptor sensitivity (Segal and Kuczenski, 1999) , non-DA mechanisms (Joyce and Iversen, 1984) , and subregions of both the dSTR and NAc (Kelly et al, 1975; Kelley et al, 1988) . Owing to our emphasis on 'low-dose' locomotor activating effects of COC and AMPH, we did not analyze the effects of 5 mg/ kg AMPH on DAT function.
In contrast to COC-treated rats, specific [ 3 H]DA uptake measured in rats given saline, 0.5 or 1 mg/kg AMPH did not differ either between ABs and AAs, or from saline. Likewise, regardless of AB/AA classification, AMPH-induced locomotor activity and [ 3 H]DA uptake were not correlated. The lack of AMPH-induced regulation of DAT activity was surprising since AMPH exposure has been shown to downregulate DAT surface expression in cells (Saunders et al, 2000) . However, only a dose of 10 mg/kg has been reported to produce downregulation measured ex vivo (Fleckenstein et al, 1997 (Fleckenstein et al, , 1999 . The lower AMPH doses in the present study (0.5 and 1 mg/kg), which were used because they induced locomotor activation similar to that seen with 10 mg/kg COC without inducing stereotypic behaviors, may be too low to induce detectable changes in [ 3 H]DA uptake and/or DAT surface expression. Alternatively, it is possible that the lack of difference in DAT function with either dose of AMPH reflects the less distinct AB/AA behavioral separation. In any case, two potentially relevant neurochemical differences that could explain the different results with COC and AMPH are that (1) the two drugs rapidly regulate DAT in an opposing manner and (2) compared to COC, the ability of AMPH to increase extracellular DA is much less dependent on neuronal activity.
While H]DA uptake can indirectly measure cell surface expression of DAT, it will be important in the future to use a direct method to confirm COC-induced differences in DAT trafficking in LCRs and HCRs. For example, cell surface DAT has been crosslinked with biotin in dSTR synaptosomes and quantified with Western blot analysis (Chi and Reith, 2003; Salvatore et al, 2003) . In addition, it will be important to examine cell surface expression of DAT in the NAc, where we initially saw both basal differences between LCRs and HCRs in in vivo DA clearance and greater COCinduced changes in DA clearance in HCRs than LCRs (Sabeti et al, 2002) . However, NAc studies will be challenging. Recent studies suggest locomotor activation is associated with the shell, but not the core (Sellings and Clarke, 2003) . Currently, we can measure [ 3 H]DA uptake only in synaptosomes prepared from the entire NAc because of its small size.
In summary, whereas 10 mg/kg COC induced considerable individual variability in locomotor activation suggestive of two subpopulations, the variability observed with AMPH (1, 0.5, and 5 mg/kg) was not as pronounced. The behavioral variation that did exist with AMPH cannot be explained by differences in cell surface expression of DAT in dSTR, as ABs and AAs displayed no differences in total DAT number, affinity, or [ 3 H]DA uptake. Interestingly, this was not the case for COC-treated rats. While LCRs and HCRs displayed no differences in total DAT number or affinity, HCRs had greater [ 3 H]DA uptake in dSTR than LCRs. Our results suggest a difference in cell surface expression of DAT that is responsible, at least in part, for the observed variability in COC-induced behavioral activation of male Sprague-Dawley rats.
The clinical implications of our findings are unknown. However, LCRs, but not HCRs, express locomotor sensitization with repeated cocaine administration (Sabeti et al, 2003) . Furthermore, differential initial responsiveness of humans to COC is related to abuse potential (Haertzen et al, 1983; Davidson et al, 1993) . Imaging studies have shown that the magnitude of DAT blockade in brain is one of the important parameters contributing to the cocaine 'high' (Volkow et al, 1999) . A lower number of transporters would be more readily blocked by a given dose of COC. Thus, the number of functional DATs undoubtedly plays an important role in cocaine reinforcement and addiction in humans.
